Cargando…
Discovery and validation of autosomal dominant Alzheimer’s disease mutations
BACKGROUND: Alzheimer’s disease (AD) is a neurodegenerative disease that is clinically characterized by progressive cognitive decline. Mutations in amyloid-β precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) are the pathogenic cause of autosomal dominant AD (ADAD). However, pol...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052673/ https://www.ncbi.nlm.nih.gov/pubmed/30021643 http://dx.doi.org/10.1186/s13195-018-0392-9 |
_version_ | 1783340706310389760 |
---|---|
author | Hsu, Simon Gordon, Brian A. Hornbeck, Russ Norton, Joanne B. Levitch, Denise Louden, Adia Ziegemeier, Ellen Laforce, Robert Chhatwal, Jasmeer Day, Gregory S. McDade, Eric Morris, John C. Fagan, Anne M. Benzinger, Tammie L. S. Goate, Alison M. Cruchaga, Carlos Bateman, Randall J. Karch, Celeste M. |
author_facet | Hsu, Simon Gordon, Brian A. Hornbeck, Russ Norton, Joanne B. Levitch, Denise Louden, Adia Ziegemeier, Ellen Laforce, Robert Chhatwal, Jasmeer Day, Gregory S. McDade, Eric Morris, John C. Fagan, Anne M. Benzinger, Tammie L. S. Goate, Alison M. Cruchaga, Carlos Bateman, Randall J. Karch, Celeste M. |
author_sort | Hsu, Simon |
collection | PubMed |
description | BACKGROUND: Alzheimer’s disease (AD) is a neurodegenerative disease that is clinically characterized by progressive cognitive decline. Mutations in amyloid-β precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) are the pathogenic cause of autosomal dominant AD (ADAD). However, polymorphisms also exist within these genes. METHODS: In order to distinguish polymorphisms from pathogenic mutations, the DIAN Expanded Registry has implemented an algorithm for determining ADAD pathogenicity using available information from multiple domains, including genetic, bioinformatic, clinical, imaging, and biofluid measures and in vitro analyses. RESULTS: We propose that PSEN1 M84V, PSEN1 A396T, PSEN2 R284G, and APP T719N are likely pathogenic mutations, whereas PSEN1 c.379_382delXXXXinsG and PSEN2 L238F have uncertain pathogenicity. CONCLUSIONS: In defining a subset of these variants as pathogenic, individuals from these families can now be enrolled in observational and clinical trials. This study outlines a critical approach for translating genetic data into meaningful clinical outcomes. |
format | Online Article Text |
id | pubmed-6052673 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60526732018-07-23 Discovery and validation of autosomal dominant Alzheimer’s disease mutations Hsu, Simon Gordon, Brian A. Hornbeck, Russ Norton, Joanne B. Levitch, Denise Louden, Adia Ziegemeier, Ellen Laforce, Robert Chhatwal, Jasmeer Day, Gregory S. McDade, Eric Morris, John C. Fagan, Anne M. Benzinger, Tammie L. S. Goate, Alison M. Cruchaga, Carlos Bateman, Randall J. Karch, Celeste M. Alzheimers Res Ther Research BACKGROUND: Alzheimer’s disease (AD) is a neurodegenerative disease that is clinically characterized by progressive cognitive decline. Mutations in amyloid-β precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) are the pathogenic cause of autosomal dominant AD (ADAD). However, polymorphisms also exist within these genes. METHODS: In order to distinguish polymorphisms from pathogenic mutations, the DIAN Expanded Registry has implemented an algorithm for determining ADAD pathogenicity using available information from multiple domains, including genetic, bioinformatic, clinical, imaging, and biofluid measures and in vitro analyses. RESULTS: We propose that PSEN1 M84V, PSEN1 A396T, PSEN2 R284G, and APP T719N are likely pathogenic mutations, whereas PSEN1 c.379_382delXXXXinsG and PSEN2 L238F have uncertain pathogenicity. CONCLUSIONS: In defining a subset of these variants as pathogenic, individuals from these families can now be enrolled in observational and clinical trials. This study outlines a critical approach for translating genetic data into meaningful clinical outcomes. BioMed Central 2018-07-18 /pmc/articles/PMC6052673/ /pubmed/30021643 http://dx.doi.org/10.1186/s13195-018-0392-9 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Hsu, Simon Gordon, Brian A. Hornbeck, Russ Norton, Joanne B. Levitch, Denise Louden, Adia Ziegemeier, Ellen Laforce, Robert Chhatwal, Jasmeer Day, Gregory S. McDade, Eric Morris, John C. Fagan, Anne M. Benzinger, Tammie L. S. Goate, Alison M. Cruchaga, Carlos Bateman, Randall J. Karch, Celeste M. Discovery and validation of autosomal dominant Alzheimer’s disease mutations |
title | Discovery and validation of autosomal dominant Alzheimer’s disease mutations |
title_full | Discovery and validation of autosomal dominant Alzheimer’s disease mutations |
title_fullStr | Discovery and validation of autosomal dominant Alzheimer’s disease mutations |
title_full_unstemmed | Discovery and validation of autosomal dominant Alzheimer’s disease mutations |
title_short | Discovery and validation of autosomal dominant Alzheimer’s disease mutations |
title_sort | discovery and validation of autosomal dominant alzheimer’s disease mutations |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052673/ https://www.ncbi.nlm.nih.gov/pubmed/30021643 http://dx.doi.org/10.1186/s13195-018-0392-9 |
work_keys_str_mv | AT hsusimon discoveryandvalidationofautosomaldominantalzheimersdiseasemutations AT gordonbriana discoveryandvalidationofautosomaldominantalzheimersdiseasemutations AT hornbeckruss discoveryandvalidationofautosomaldominantalzheimersdiseasemutations AT nortonjoanneb discoveryandvalidationofautosomaldominantalzheimersdiseasemutations AT levitchdenise discoveryandvalidationofautosomaldominantalzheimersdiseasemutations AT loudenadia discoveryandvalidationofautosomaldominantalzheimersdiseasemutations AT ziegemeierellen discoveryandvalidationofautosomaldominantalzheimersdiseasemutations AT laforcerobert discoveryandvalidationofautosomaldominantalzheimersdiseasemutations AT chhatwaljasmeer discoveryandvalidationofautosomaldominantalzheimersdiseasemutations AT daygregorys discoveryandvalidationofautosomaldominantalzheimersdiseasemutations AT mcdadeeric discoveryandvalidationofautosomaldominantalzheimersdiseasemutations AT morrisjohnc discoveryandvalidationofautosomaldominantalzheimersdiseasemutations AT faganannem discoveryandvalidationofautosomaldominantalzheimersdiseasemutations AT benzingertammiels discoveryandvalidationofautosomaldominantalzheimersdiseasemutations AT goatealisonm discoveryandvalidationofautosomaldominantalzheimersdiseasemutations AT cruchagacarlos discoveryandvalidationofautosomaldominantalzheimersdiseasemutations AT batemanrandallj discoveryandvalidationofautosomaldominantalzheimersdiseasemutations AT discoveryandvalidationofautosomaldominantalzheimersdiseasemutations AT karchcelestem discoveryandvalidationofautosomaldominantalzheimersdiseasemutations |